

Danielle J Vugts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/990000/publications.pdf>

Version: 2024-02-01

97
papers

4,170
citations

87888

38
h-index

123424

61
g-index

101
all docs

101
docs citations

101
times ranked

5249
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Study of ⁸⁹ Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 362-367. | 5.0 | 44 |
| 2 | Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2020-2029. | 7.0 | 18 |
| 3 | Immuno-PET Imaging of Atherosclerotic Plaques with [⁸⁹ Zr]Zr-Anti-CD40 mAb—Proof of Concept. <i>Biology</i> , 2022, 11, 408. | 2.8 | 3 |
| 4 | The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor. <i>Pharmaceuticals</i> , 2022, 15, 450. | 3.8 | 6 |
| 5 | Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [⁸⁹ Zr]Zr-DFO-PEG ₅ -Tz. <i>Bioconjugate Chemistry</i> , 2022, 33, 956-968. | 3.6 | 2 |
| 6 | PET-CT Imaging of Polymeric Nanoparticle Tumor Accumulation in Patients. <i>Advanced Materials</i> , 2022, 34, e2201043. | 21.0 | 19 |
| 7 | Pre-targeting with ultra-small nanoparticles: boron carbon dots as drug candidates for boron neutron capture therapy. <i>Journal of Materials Chemistry B</i> , 2021, 9, 410-420. | 5.8 | 17 |
| 8 | The Role of ⁸⁹ Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals. <i>Journal of Nuclear Medicine</i> , 2021, 62, 438-445. | 5.0 | 39 |
| 9 | Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical ⁸⁹ Zr-immuno-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 694-707. | 6.4 | 43 |
| 10 | Fluorine-18 labelled Ruppert-Prakash reagent ([¹⁸ F]Me ₃ SiCF ₃) for the synthesis of ¹⁸ F-trifluoromethylated compounds. <i>Chemical Communications</i> , 2021, 57, 5286-5289. | 4.1 | 8 |
| 11 | State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET. <i>Bioconjugate Chemistry</i> , 2021, 32, 1315-1330. | 3.6 | 37 |
| 12 | Performance of nanoScan PET/CT and PET/MR for quantitative imaging of ¹⁸ F and ⁸⁹ Zr as compared with ex vivo biodistribution in tumor-bearing mice. <i>EJNMMI Research</i> , 2021, 11, 57. | 2.5 | 6 |
| 13 | Towards PET imaging of the dynamic phenotypes of microglia. <i>Clinical and Experimental Immunology</i> , 2021, 206, 282-300. | 2.6 | 28 |
| 14 | The Race for Hydroxamate-Based Zirconium-89 Chelators. <i>Cancers</i> , 2021, 13, 4466. | 3.7 | 23 |
| 15 | Evaluating N-ethylfluoromethyltriazolium triflate as a precursor for the synthesis of high molar activity [¹⁸ F]fluoroform. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2021, 64, 466-476. | 1.0 | 5 |
| 16 | Meet the editors: Danielle Vugts. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2021, 64, 489-491. | 1.0 | 0 |
| 17 | Comparison of analytical methods for antibody conjugates with application in nuclear imaging — Report from the trenches. <i>Nuclear Medicine and Biology</i> , 2021, 102-103, 24-33. | 0.6 | 1 |
| 18 | State of the art of radiochemistry for ¹¹ C and ¹⁸ F PET tracers. , 2021, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | PET Imaging of Purinergic Receptors. , 2021, , 879-889. | | 1 |
| 20 | Synthesis and evaluation of [18F]cinacalcet for the imaging of parathyroid hyperplasia. Nuclear Medicine and Biology, 2021, 102-103, 97-105. | 0.6 | 2 |
| 21 | Novel Thienopyrimidine-Based PET Tracers for P2Y ₁₂ Receptor Imaging in the Brain. ACS Chemical Neuroscience, 2021, 12, 4465-4474. | 3.5 | 15 |
| 22 | The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 379-389. | 6.4 | 44 |
| 23 | [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 849-859. | 6.4 | 22 |
| 24 | In vivo tracking of single cells with PET. Nature Biomedical Engineering, 2020, 4, 765-766. | 22.5 | 6 |
| 25 | Design, Synthesis, Conjugation, and Reactivity of Novel <i>trans,trans</i> -1,5-Cyclooctadiene-Derived Bioorthogonal Linkers. Bioconjugate Chemistry, 2020, 31, 2201-2210. | 3.6 | 6 |
| 26 | PET imaging of P2X7R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [11C]SMW139. Journal of Neuroinflammation, 2020, 17, 300. | 7.2 | 15 |
| 27 | The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by ⁸⁹ Zr-immuno-PET in xenograft bearing mice. Theranostics, 2020, 10, 5815-5828. | 10.0 | 25 |
| 28 | Design, Synthesis, Radiosynthesis and Biological Evaluation of Fenretinide Analogues as Anticancer and Metabolic Syndrome-Preventive Agents. ChemMedChem, 2020, 15, 1579-1590. | 3.2 | 2 |
| 29 | Total-Body PET and Highly Stable Chelators Together Enable Meaningful ⁸⁹ Zr-Antibody PET Studies up to 30 Days After Injection. Journal of Nuclear Medicine, 2020, 61, 453-460. | 5.0 | 66 |
| 30 | Synthesis of [¹⁸ F]Fluoroform with High Molar Activity. European Journal of Organic Chemistry, 2020, 2020, 1177-1185. | 2.4 | 17 |
| 31 | Altered splenic [Zr]Zr-rituximab uptake in patients with interstitial lung disease not responding to rituximab: could this indicate a splenic immune-mediated mechanism?. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 168-177. | 1.0 | 0 |
| 32 | The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented?. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 2. | 3.9 | 9 |
| 33 | The biodistribution and clearance of AlbuAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans. EJNMMI Research, 2019, 9, 45. | 2.5 | 12 |
| 34 | Immunoglobulins as Radiopharmaceutical Vectors. , 2019, , 163-179. | | 3 |
| 35 | Perioperative PET/CT lymphoscintigraphy and fluorescent real-time imaging for sentinel lymph node mapping in early staged colon cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1495-1505. | 6.4 | 16 |
| 36 | Immuno-PET Imaging to Assess Target Engagement: Experience from ⁸⁹ Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors. Journal of Nuclear Medicine, 2019, 60, 902-909. | 5.0 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-Guided Translational Approach. <i>Molecular Pharmaceutics</i> , 2019, 16, 273-281. | 4.6 | 20 |
| 38 | Fully Automated ⁸⁹ Zr Labeling and Purification of Antibodies. <i>Journal of Nuclear Medicine</i> , 2019, 60, 691-695. | 5.0 | 19 |
| 39 | First-in-human imaging of nanoparticle entrapped docetaxel (CPC634) in patients with advanced solid tumors using ⁸⁹ Zr-Df-CPC634 PET/CT. <i>Journal of Clinical Oncology</i> , 2019, 37, 3093-3093. | 1.6 | 3 |
| 40 | [⁸⁹ Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis: a feasibility study. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 9, 296-308. | 1.0 | 5 |
| 41 | Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images. <i>Molecular Imaging and Biology</i> , 2018, 20, 1025-1034. | 2.6 | 13 |
| 42 | Identification of the allosteric P2X7 receptor antagonist [¹¹ C]SMW139 as a PET tracer of microglial activation. <i>Scientific Reports</i> , 2018, 8, 6580. | 3.3 | 54 |
| 43 | Feasibility of PET/CT system performance harmonisation for quantitative multicentre ⁸⁹ Zr studies. <i>EJNMMI Physics</i> , 2018, 5, 26. | 2.7 | 18 |
| 44 | Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. <i>Nature Communications</i> , 2018, 9, 4664. | 12.8 | 331 |
| 45 | Identification of new molecular targets for PET imaging of the microglial anti-inflammatory activation state. <i>Theranostics</i> , 2018, 8, 5400-5418. | 10.0 | 48 |
| 46 | PET Imaging of Microglial Activation – Beyond Targeting TSPO. <i>Molecules</i> , 2018, 23, 607. | 3.8 | 85 |
| 47 | Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody. <i>EJNMMI Research</i> , 2018, 8, 6. | 2.5 | 11 |
| 48 | Fast and reliable generation of [¹⁸ F]triflyl fluoride, a gaseous [¹⁸ F]fluoride source. <i>Chemical Communications</i> , 2018, 54, 10179-10182. | 4.1 | 23 |
| 49 | High resolution combined molecular and structural optical imaging of colorectal cancer in a xenograft mouse model. <i>Biomedical Optics Express</i> , 2018, 9, 6186. | 2.9 | 19 |
| 50 | ⁸⁹ Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding. <i>Oncotarget</i> , 2018, 9, 24737-24749. | 1.8 | 24 |
| 51 | Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. <i>Onc Immunology</i> , 2017, 6, e1277306. | 4.6 | 190 |
| 52 | Fluorine-18 labelled building blocks for PET tracer synthesis. <i>Chemical Society Reviews</i> , 2017, 46, 4709-4773. | 38.1 | 150 |
| 53 | PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 267-273. | 0.6 | 48 |
| 54 | Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X ₇ Receptor Antagonist. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2374-2380. | 3.5 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | ESPMIS: Helping Young Scientists Navigate the Molecular Imaging Landscape. <i>Molecular Imaging and Biology</i> , 2017, 19, 325-327. | 2.6 | 0 |
| 56 | Molecular Drug Imaging: ⁸⁹ Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 711-716. | 5.0 | 69 |
| 57 | Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for ⁸⁹ Zr-immuno-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 286-295. | 6.4 | 111 |
| 58 | Performance of ⁸⁹ Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>PLoS ONE</i> , 2017, 12, e0169828. | 2.5 | 50 |
| 59 | Pharmacokinetics of cetuximab and tumor uptake of ⁸⁹ Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15117-e15117. | 1.6 | 2 |
| 60 | Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice. <i>PLoS ONE</i> , 2017, 12, e0176075. | 2.5 | 30 |
| 61 | Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. <i>Oncotarget</i> , 2017, 8, 3870-3880. | 1.8 | 48 |
| 62 | Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?. <i>Frontiers in Pharmacology</i> , 2016, 7, 131. | 3.5 | 152 |
| 63 | B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2016, 18, 266. | 3.5 | 36 |
| 64 | HDL mimetic CER-001 targets atherosclerotic plaques in patients. <i>Atherosclerosis</i> , 2016, 251, 381-388. | 0.8 | 51 |
| 65 | Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of ⁸⁹ Zr-Bevacizumab PET Imaging in Brain Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2166-2174. | 4.1 | 51 |
| 66 | Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 425-441. | 3.8 | 63 |
| 67 | Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. <i>Annals of Oncology</i> , 2016, 27, 619-624. | 1.2 | 269 |
| 68 | Tumour targeting and radiation dose of radioimmunotherapy with ⁹⁰ Y-rituximab in CD20+ B-cell lymphoma as predicted by ⁸⁹ Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1304-1314. | 6.4 | 76 |
| 69 | ⁸⁹ Zr-cetuximab PET imaging in patients with advanced colorectal cancer. <i>Oncotarget</i> , 2015, 6, 30384-30393. | 1.8 | 106 |
| 70 | ⁸⁹ Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 59, 18-38. | 0.7 | 38 |
| 71 | Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101). <i>PLoS ONE</i> , 2014, 9, e82331. | 2.5 | 207 |
| 72 | Preclinical evaluation of ⁸⁹ Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys. <i>MAbs</i> , 2014, 6, 567-575. | 5.2 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Synthesis and initial preclinical evaluation of the P2X ₇ receptor antagonist [¹¹ C]A ϵ 740003 as a novel tracer of neuroinflammation. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 509-516. | 1.0 | 70 |
| 74 | A Universal Procedure for the [¹⁸ F]Trifluoromethylation of Aryl Iodides and Aryl Boronic Acids with Highly Improved Specific Activity. Angewandte Chemie - International Edition, 2014, 53, 11046-11050. | 13.8 | 84 |
| 75 | Development of Novel ADCs: Conjugation of Tubulysin Analogues to Trastuzumab Monitored by Dual Radiolabeling. Cancer Research, 2014, 74, 5700-5710. | 0.9 | 69 |
| 76 | Multicenter Harmonization of ⁸⁹ Zr PET/CT Performance. Journal of Nuclear Medicine, 2014, 55, 264-267. | 5.0 | 63 |
| 77 | Pilot study of ⁸⁹ Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer. EJNMMI Research, 2014, 4, 35. | 2.5 | 43 |
| 78 | ImmunoPET imaging with ⁸⁹ Zr-cetuximab in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 11102-11102. | 1.6 | 2 |
| 79 | Imaging Histamine Receptors Using PET and SPECT. , 2014, , 331-376. | | 0 |
| 80 | Efficient synthesis of [¹⁸ F]trifluoromethane and its application in the synthesis of PET tracers. Chemical Communications, 2013, 49, 4018. | 4.1 | 42 |
| 81 | Tumour imaging by Positron Emission Tomography using fluorinase generated 5-[¹⁸ F]fluoro-5-deoxyribose as a novel tracer. Nuclear Medicine and Biology, 2013, 40, 464-470. | 0.6 | 27 |
| 82 | Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging. Nature Protocols, 2013, 8, 1010-1018. | 12.0 | 50 |
| 83 | Pilot Study on the Feasibility of PET/CT Lymphoscintigraphy with ⁸⁹ Zr-Nanocolloidal Albumin for Sentinel Node Identification in Oral Cancer Patients. Journal of Nuclear Medicine, 2013, 54, 585-589. | 5.0 | 48 |
| 84 | Phase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients. Journal of Nuclear Medicine, 2013, 54, 397-401. | 5.0 | 47 |
| 85 | ¹¹ C-labeled and ¹⁸ F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 120-129. | 1.0 | 21 |
| 86 | ⁸⁹ Zr-PET Radiochemistry in the Development and Application of Therapeutic Monoclonal Antibodies and Other Biologicals. Current Topics in Medicinal Chemistry, 2013, 13, 446-457. | 2.1 | 39 |
| 87 | ⁹⁰ Nb - a potential PET nuclide: production and labeling of monoclonal antibodies. Radiochimica Acta, 2012, 100, 857-864. | 1.2 | 25 |
| 88 | PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumor Biology, 2012, 33, 607-615. | 1.8 | 81 |
| 89 | ⁸⁹ Zr-labeled compounds for PET imaging guided personalized therapy. Drug Discovery Today: Technologies, 2011, 8, e53-e61. | 4.0 | 33 |
| 90 | Synthesis of Phosphine and Antibody-Azide Probes for <i>in Vivo</i> Staudinger Ligation in a Pretargeted Imaging and Therapy Approach. Bioconjugate Chemistry, 2011, 22, 2072-2081. | 3.6 | 53 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 91 | Synthesis of 3-Deoxyribolactones using a Hydrolysis-Induced Lactonization Cascade Reaction of Epoxy Cyanohydrins. <i>European Journal of Organic Chemistry</i> , 2008, 2008, 1336-1339. | 2.4 | 4 |
| 92 | A Multicomponent Synthesis of Triazinane Diones. <i>Journal of Organic Chemistry</i> , 2008, 73, 719-722. | 3.2 | 45 |
| 93 | Diastereoselective Multicomponent Synthesis of Dihydropyridones with an Isocyanide Functionality. <i>Organic Letters</i> , 2006, 8, 5369-5372. | 4.6 | 48 |
| 94 | Multicomponent Synthesis of Dihydropyrimidines and Thiazines. <i>Chemistry - A European Journal</i> , 2006, 12, 7178-7189. | 3.3 | 68 |
| 95 | A Mild Chemo-Enzymatic Oxidation-Hydrocyanation Protocol. <i>European Journal of Organic Chemistry</i> , 2006, 2006, 1672-1677. | 2.4 | 35 |
| 96 | Methylene-Azaphosphirane as a Reactive Intermediate. <i>Chemistry - A European Journal</i> , 2005, 11, 4808-4818. | 3.3 | 13 |
| 97 | A novel four-component reaction for the synthesis of functionalised dihydropyrimidines Electronic supplementary information (ESI) available: ¹ H and ¹³ C NMR data for 9 and 10. See http://www.rsc.org/suppdata/cc/b3/b308243a . <i>Chemical Communications</i> , 2003, , 2594. | 4.1 | 38 |